- Monitors to Improve Indoor Carbon Dioxide Concentrations in the
- 2 Hospital: Background, Rationale and Protocol for a Randomized,
- 3 Sham-controlled, Cross-Over, Open Label Trial
- 4 Michaël R. Laurent ¹, Johan Frans ²
- 1. Geriatrics Department, Imelda Hospital, Bonheiden, Belgium. https://orcid.org/0000-
- 6 0001-9681-8330

- 7 2. Department of Medical Microbiology, Imelda Hospital, Bonheiden, Belgium.
- 8 https://orcid.org/0000-0002-0440-8383
- 9 Correspondence:
- 10 Dr. Michaël R. Laurent, MD PhD
- 11 Imeldalaan 9, 2820 Bonheiden, Belgium
- 12 <u>michael.laurent@imelda.be</u>; Tel. +32 15 505103
- 13 Author contribution statement:
- 14 Conceptualization (equal), Resources (equal), Data curation (ML), Formal analysis (ML),
- 15 Investigation (equal), Methodology (equal), Project administration (ML), Writing original
- draft (equal), Writing review & editing (equal), Approval of the final manuscript (equal).
- 17 **Ethics approval statement:** The study protocol was reviewed and approved by the
- 18 Institutional Review Board of Imelda Hospital, Bonheiden, Belgium.
- 19 Patient consent statement: not applicable
- 20 **Data availability statement**: Following publication, all data supporting this manuscript will be
- 21 made available to established investigators upon simple request.
- 22 **Funding statement**: The authors report no external funding related to this work.
- 23 Conflict of interest disclosure: Dr. Laurent has received consultancy and lecture fees from
- 24 Alexion, Amgen, Kyowa Kirin, Menarini, Sandoz, Takeda, UCB, and Will-Pharma, none of
- 25 which are related to this work.
- 26 **Permission to reproduce material from other sources:** not applicable
- 27 **Short running title:** CO2 monitors in hospital: trial protocol
- 28 **Acknowledgement:** We thank the staff of the geriatrics department for their participation in
- 29 the study.

ABSTRACT

30

31 32

33

34

35

36

37

38

39

40

41

42 43

44

45 46

47

48

51

Coronavirus disease 2019 (COVID-19) has caused considerably morbidity and mortality worldwide, mainly among older adults. Hospital outbreaks contribute to the burden of this disease, despite optimal hand hygiene and personal protective equipment such as masks and face shields. Ventilation with fresh outdoor air has emerged as an important strategy to reduce indoor aerosol transmission of COVID-19. Carbon dioxide (CO₂) monitors are increasingly advocated to facilitate ventilation in schools, long-term care facilities, offices and public buildings. Moreover, several health authorities have issued guidelines for target CO₂ values in work as well as clinical environments. Given that modern hospitals have superior indoor air quality control systems, it remains however unknown whether feedback from CO2 monitors is needed and/or effective to improve ventilation further. Here, we describe the rationale and protocol for a randomized, sham-controlled, crossover, open label trial of CO₂ monitors in double-bed hospital rooms in two acute geriatric wards. Based on pilot data, Aranet4 Home® monitors will be used to alert nurses and other staff to raised indoor CO2 concentrations. Practical limitations in implementing CO₂ monitors are discussed, and will be surveyed among staff as additional study outcomes. The Monitors to Improve Indoor Carbon Dioxide (CO₂) Concentrations in the Hospital (MICH) trial is registered at ClinicalTrials.gov, identifier: NCT04770597.

Keywords: Carbon dioxide; coronavirus disease 2019; Geriatrics; Healthcare-associated
 Infections; Hospitals; Ventilation.

1. INTRODUCTION

52

53

54

55

56 57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

The coronavirus disease 2019 (COVID-19) pandemic has posed a high burden on societies, healthcare systems and long-term care facilities worldwide. COVID-19 has caused considerably morbidity and mortality, particularly in frail older adults [1], [2]. While there is little direct evidence for any transmission route, there is accumulating evidence for respiratory transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, the virus which causes COVID-19), not only via droplets but also via smaller particles in aerosols, mainly in closed spaces [3], [4], [5]. Nosocomial transmission contributes to the incidence and mortality of COVID-19 [2], [6], [7]. Acute medical and surgical wards in particular host many older adults close together. Therefore, unprecedented infection control measures have been implemented in hospitals since 2020. These include universal mask wearing by patients and caregivers, increased attention to hand and surface disinfection, and screening patients and/or staff for SARS-CoV-2 [8]. Other measures include physical distancing among staff and use of mobile highefficiency particulate air (HEPA)-filters. Nevertheless, clusters of SARS-CoV-2 transmission have been documented despite all these countermeasures [6]. Exposure to an infected patient for at least 15 minutes is a documented risk factor in this regard [6]. Ventilation with fresh outdoor air is increasingly highlighted as a strategy to avoid indoor aerosol transmission of respiratory pathogens [9]. One convenient surrogate parameter for ventilation in this context, is the indoor carbon dioxide (CO₂) concentration [10]. Humans exhale CO₂ at concentrations of almost 40 000 p.p.m. [11], compared to outdoor concentrations which have increased in recent years to values averaging ~450 p.p.m. (fluctuating between 400-500 p.p.m.). Thus, in the absence of combustion, animals and certain chemical reactions (which also produce CO₂) or plants (which catalyze CO₂ during photosynthesis), the increase in CO₂ concentrations above outdoor levels, reflects the indoor concentration of human exhaled air (potentially carrying respiratory pathogens). The total amount of CO₂ which humans exhale is determined by their respiratory minute volume or oxygen consumption (which correlates with physical activity) and their metabolic respiratory quotient (ratio of CO₂ exhaled to oxygen consumed, which is influenced by diet and metabolic factors). Rudnik & Milton reported that under average circumstances, an indoor CO₂ concentration > 380 p.p.m. above outside levels implies that inhaled air contains 1% exhaled air [11]. In turn, this rebreathed fraction or "shared air" correlates with the basic reproductive number of respiratory infections [11]. On the other hand, increased ventilation (particularly displacement ventilation [12]) could also facilitate spreading of pathogens if the air flows from the contaminant source towards susceptible, unmasked individuals [13], [14].

88

89

90

91

92

93

94

95

96

97

98 99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116117

118

119120

121

There is no universal agreement on optimal cut-offs for indoor CO₂ concentrations in general, or in the context of COVID-19 in particular. Regulatory bodies in several countries have proposed guidelines to maintain indoor CO₂ concentrations below values typically ranging from 800 to 1000 p.p.m. [15], [16], [17]. One COVID-19 cluster in a Dutch nursing home was associated with the use of an energy-saving CO₂-driven ventilation system, which maintained indoor CO₂ concentrations around 1000 p.p.m. [18]. It should be noted that indoor air quality standards for buildings sometimes refer to average CO2 levels over prolonged time periods (e.g. 8 hours [19]), although the risk of respiratory infections also applies to shorter exposures [6], [11]. As the COVID-19 pandemic continues, CO₂ monitors are increasingly deployed and recommended (for example, in countries like Germany or Norway [17]) to monitor ventilation and prevent aerosol transmission of SARS-CoV-2 in schools, long-term care facilities, offices and public buildings [15], [17], [20]. Some experts have called for the use of CO₂ monitors by nurses in hospitals and nursing homes too [20]. However, empirical evidence supporting the use of CO₂ monitors to improve ventilation (let alone to prevent COVID-19) in any setting is lagging behind. Modern hospitals, particularly operating and delivery rooms, intensive care units and microbiology laboratories, are equipped with superior heating, ventilation and air conditioning (HVAC) systems, which also remove particles via HEPA filters. For normal patient rooms however, the recommended outdoor and total air change rates per hour are only 2 and 4, respectively [21]. While these rates may be sufficient to meet indoor air quality requirements for patients, they may be temporarily insufficient when patient rooms are crowded by visitors or healthcare staff. Indeed, physical distancing and limiting occupant density, which are commonly recommended in stores, offices and public buildings, are challenging in hospitals, since patients depend on caregivers. In one study, CO₂ production in hospital rooms correlated with room entries (indicated by infrared beam breaks) [22]. Moreover, opening windows in hospital may be avoided due to thermal and draft discomfort [13], [23] or risk of patient injury from falling out the window [24]. Few studies have actually reported indoor CO₂ concentrations in hospitals [13]. Inappropriately high CO₂ concentrations have been reported in hospitals without modern HVAC systems in Brazil (reaching peaks over 3000 p.p.m) [25] and China (daily averages > 1000 p.p.m.) [23]. In contrast, excellent CO₂ values were reported in an Iranian intensive care unit [26] and a new hospital building in the United States (daily average CO₂ < 150 p.p.m. above outside levels) [22]. A French study reported maximal CO₂ concentrations of 1121 to 1325 p.p.m. in a hospital nursing care room and plaster room, respectively [27]. In a

123

124

125126

127

128

129

130

131

132133

134

135

136

137

138

139

140 141

142

143

144

145

146

147

Taiwanese four-bed intensive care unit room, CO₂ levels (range 828-1570 p.p.m.) were above 1000 p.p.m. during visitor hours 92% of the year [28]. Another study from Taiwan reported that among hospital sites, patient wards had the highest average CO₂ concentration (1063 ± 483 p.p.m., N=3 hospitals) [29]. Thus, it is clear that despite guidelines for hospital HVAC systems and CO₂ targets in buildings, ventilation in regular wards may be worse than commonly appreciated. Most studies have reported daily average CO₂ levels or maximal levels during short measurement periods. More research is needed not only to provide a more detailed overview of indoor CO₂ fluctuations in hospital rooms, but even more so to define optimal strategies to maintain CO₂ below recommended maximum levels. Interestingly, Yang et al. reported daily peaks > 1000 p.p.m. in the hospital environment, which could be mitigated using an integrated monitoring system which alerted medical supervisors and automatically activated ventilation [19]. Given this background, the authors launched a prospective interventional study to assess the efficacy and feasibility of monitors to maintain indoor CO2 concentrations in their hospital below 800 - 1000 p.p.m. Here, we describe the rationale and pilot data supporting the design and protocol of the "Monitors to Improve Indoor Carbon Dioxide Concentrations in the Hospital" (MICH) randomized trial. 2. PROTOCOL This trial protocol (version 2.0, April 9th, 2020) is reported in accordance with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 statement [30]. The SPIRIT checklist is provided (**Supplementary Table 1**). 2.1. Study design This study is a randomized, sham-controlled, open-label, crossover superiority trial, performed consecutively in two acute geriatric wards. In each ward, six double bed rooms will be fitted with Aranet4 Home[®] CO₂ monitors, which constitute the unit of randomization. The crossover design involves three phases, each lasting seven days (Figure 1).




Figure 1: Study design overview.

- 1. **Pre-intervention (baseline) period (1 week):** all monitors facing downwards, with staff blinded to measurements.
- 2. Intervention period (2 x 1 weeks): Each monitor will be randomized either to be visible to the clinical staff for one week, or in the sham-controlled group, to be turned with the screen facing downwards for one week. After one week, the monitors cross over to the other group (AB/BA crossover design) for one week. After two weeks, the sensors will be removed from the first ward and moved for three weeks to the second ward. Thus, the duration of the trial is seven weeks per ward, and ten weeks in total.
- Post-intervention period (1 week): after a three week interval, the sensors are
 again installed in six double-bed rooms, with their display facing downwards and staff
 blinded to the measurements.

Given the open-label design, the sham-control group was chosen to take potential observation bias (Hawthorne effect) and carryover effects into account. The primary and secondary endpoints will be compared between the active and sham-controlled groups in the intervention phase. However, because we expect some carry-over effects from the intervention to the sham groups, pre-planned analyses will compare the intervention against the pre-intervention phase. Furthermore, comparison between the intervention and post-intervention phase will allow us to investigate whether significant wear-off effects can be demonstrated or not.

Sensors will be randomized by the investigators to the sham/intervention or intervention/sham arm respectively, immediately prior to the intervention using an online random sequence generator (1:1 ratio, N = 1 block size). Due to the nature of the intervention, allocation concealment is not possible. Investigators performing the analysis will also not be blinded to intervention groups. However, the *a priori* statistical analysis plan and the availability of data for independent review by other scientists mitigates the risk of bias from this source. Data will be analyzed using the intention-to-treat principle, *e.g.* even when the monitors in the sham group are unblinded or *vice versa*.

2.2. Setting

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

This single-center trial will run at the Geriatrics Department, which is located in the oldest wing of Imelda general hospital in the rural area of Bonheiden, Belgium. The hospital is surrounded by nature and there is no traffic or other nearby CO₂ source. Our department has 69 acute beds (single- and double-bed rooms) divided over three wards, and one rehabilitation ward with 20 beds (transformed into a dedicated COVID-19 unit during the study). Among general acute wards with standard air exchange rates, the Geriatric Department was selected for several reasons. First, bed occupancy rate in the department is typically > 90 %. Secondly, almost all patients require assistance from staff for activities of daily living such as washing, dressing, meals etc. Thirdly, geriatrics has higher staffing levels than other acute wards and many nursing students (up to 10/ward). All these elements increase room crowding. On the other hand, many older patients have low levels of physical activity and thus low respiratory minute volumes. Visitors were also allowed very restrictively due to the ongoing COVID-19 epidemic, typically only 1 hour/week during most of the study period (with exceptions for patients receiving palliative care, which are however typically housed in single rooms). The latter elements may be associated with lower indoor CO₂ concentrations. For this study, we selected two acute wards with near-identical architecture, on the first and second floor (our third ward having slightly more spacious rooms). All rooms recently had air conditioning installed (cooling mode only). Outdoor CO₂ concentrations will be measured on an unused terrace immediately adjacent to the wards. The position of the sensors, along with the location and size of the respective double-bed rooms is illustrated in Figure 2. The patient rooms all had a similar surface area of ~20-21 m² and a 3-4 m² bathroom. The doctor's office is 23.5 m² and hosts 2 geriatricians, 1-2 registrars and 2-4 trainees.




Figure 2: Position of the sensors and double-bed rooms during the study. **A:** Three-dimensional representation of the ward showing the position of the six sensors (small red squares) in the double-bed rooms, the doctor's office (*right*) and the outdoor CO₂ sensor (*bottom left*). **B (inset):** Representative room photograph. The arrow indicates the position of the sensor on the overhead light box.

2.3. Intervention

This study will use six Aranet4 Home[®] and one Airthings Wave Plus[®] monitor (measurement ranges 0-9999 p.p.m. and 400-5000 p.p.m., respectively). Both monitors are commercially available in Europe and use non-dispersive infra-red CO₂ sensors with ± 3 % accuracy reported by the manufacturer, and raw data logging with time stamps. The Aranet[®] sensors are factory-calibrated, recommended for use in schools by the Federation of European HVAC Associations [31], and have been shown to be reliable compared to research-grade instruments and to reflect ventilation rates in a clinical environment [32]. The Airthings[®] instrument was used after the seven-day self-calibration period. When we crosscalibrated our devices (*i.e.*, putting all sensors next to each other), they displayed near-identical values. We also compared the CO₂ values from Aranet4 Home[®] to a professional indoor climate multimeter (Testo[®] 435-1) which showed identical measurement values. The sensors will be placed in the room at a height between 1 and 2 meters and not near the window or door.

222

223

224

225

226227

228

229

230

231232

233

234235

236237

238

239

240241

242

243

244

245246

247248

249

Pilot data suggested that the highest CO₂ concentrations were observed in patient rooms (Figure 3, and other data not shown), in line with previous literature [27]. When measured in the doctor's office, CO₂ values peaked during office hours but remained < 1000 p.p.m. (median 601 p.p.m., range 453 – 984 p.p.m.). We selected the Aranet4 Home® for use in the patient rooms because, in contrast to the Airthings Wave Plus[®], it has a display showing current CO₂ levels and because it can be set to bleep when threshold values are exceeded. Moreover, it proved to be more responsive, which was partly but not completely explained by its superior time-resolution (measurements possible at one-minute intervals, compared to 5 minutes with Airthings Wave Plus®), as shown in Figure 3B. Median (range) CO₂ values were 653 p.p.m. (541 - 1367 p.p.m.) with the Airthings Wave Plus[®] vs. 689 p.p.m. (548 -1540 p.p.m.) with Aranet4 Home[®], difference in medians -36 p.p.m. (95% confidence interval -41 to -32, P < 0.0001 by Wilcoxon matched-pairs signed rank test). The values were not normally distributed (P < 0.0001 D'Agostino-Pearson omnibus K2 test) and significantly paired (Spearman rs 0.9344, P < 0.0001). The Aranet® monitor data will be analyzed using two-minute bins due to ongoing technical problems with the stability of the Bluetooth® connection to Android® devices. We will use the Airthings Wave Plus® to monitor outside CO₂ levels continuously during the trial.




Figure 3. A: Indoor CO₂ measured using Airthings Wave Plus[®] sensor in the doctor's office (non-patient area) during one working week. CO₂ levels increased during office hours and returned to outside CO₂ levels (*dashed line*) by next morning. One window and door remained almost constantly open. Staff were blinded and unaware of measurements. **B:** Pilot data showing indoor CO₂ concentrations in a double-bed patient room over a 27-hour period, measured simultaneously with an Aranet4 Home[®] and an Airthings Wave Plus[®] monitor. A slight delay can be seen as an offset with the Airthings Wave Plus[®] sensor. Staff were blinded to measurements. Dashed line indicates median outdoor CO₂ concentrations.

At the start of the randomized intervention period, clinical staff on each ward will be educated by the principal investigator on the purpose and methods of the trial and strategies to improve ventilation. During the two-week intervention period, staff will be interviewed at least

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

every three days regarding difficulties in achieving CO₂ targets, and additional behavioral interventions will be sought to facilitate implementation. For example, in the intervention group, signs in the patient rooms will alert clinical staff to the ongoing experiment and CO₂ targets. Following the two-week sham/intervention phase, an anonymous online survey will be sent to ward staff to collect quantitative feedback regarding feasibility and preference to use CO2 monitors (using a 10-point Likert scale). The survey will also collect feedback about whether or not staff took action to increase ventilation, their knowledge about the primary CO₂ target used during the study and the most important challenges to implement a CO₂ monitoring strategy. We will specifically inquire about staff concerns for patient harms e.g. from cold or draft discomfort. Hospital-wide COVID-19 clusters will be recorded during the study, but this trial is not intended nor powered for clinical outcomes. 2.4. Statistical analysis plan Our primary hypothesis (primary endpoint) is that the CO₂ monitors will record less time/day (in minutes) with elevated CO₂ levels (> 800 p.p.m.) during the intervention period, compared to the sham period. Intervention vs. sham control groups will be compared using unpaired t test or Mann-Whitney U test, depending on whether or not the Gaussian distribution of the data is rejected by the D'Agostino-Pearson (omnibus K2) normality test. Secondary outcomes include the time with CO2 > 1000 p.p.m. or > 1400 p.p.m. (which are the built-in cut-off levels for orange and red warning lights on the Aranet® devices), analyzed using similar statistics. Other outcomes include survey responses (see "Intervention" section above). It is possible (and allowed) that staff applies behaviors that influence CO₂ levels also in sham rooms. Therefore, the crossover design is applied, with carry-over effects investigated by comparing the Intervention periods to the baseline period. The four periods (baseline, sham, intervention and post-intervention) will be analyzed by one-way ANOVA (or repeated measures ANOVA, if the room-level values are significantly paired) with Dunn's multiple comparisons post-test (or non-parametric Kruskal-Wallis test if not normally distributed) comparing the intervention period against the baseline, sham and post-intervention periods (3 comparisons). The only exclusion criterion is incomplete occupancy i.e. when the doublebed rooms are not fully occupied before 12 a.m., measurements from that day will be excluded. Missing data will not be imputated. A priori, we assume to interpret the results as follows: When the intervention vs. sham comparison is significant (regardless of the other

comparisons), an effect beyond sham will be assumed

- If this is the case, a significant difference between baseline and intervention will be considered further supportive observational evidence of an intervention carry-over effect (though not required to confirm the randomized intervention vs. sham comparison)
- If this is the case, a significant difference between the intervention and postintervention phase will be considered supportive observational evidence of a wear-off (or time trend) effect
- If the intervention vs. baseline AND intervention vs. post-intervention comparison are significant (but not intervention vs. sham, which could be masked by carry-over effects), a pre-post effect of the intervention will be assumed.
- If only the intervention vs. baseline comparison yields significant results, a hypothesis-generating effect of the intervention could be considered.

Statistical analyses will be performed using GraphPad Prism software. Two-tailed a below 0.05 will be considered as significant. Due to lack of sufficient pilot data for robust power calculation, we assume a conventional moderate effect size (f = 0.25). With an α error probability of 0.05, power of 0.95 and four groups, we calculate total sample size at n=280. With four groups, six sensors, two wards, seven days of measurements and expecting 15 % excluded values due to unoccupied rooms (N = 4 x 6 x 2 x 7 x 0.85 = 285.6), our trial should be powered to detect a moderate effect size. Power calculation was performed using G*Power software version 3.1.9.7 (Kiel University, Germany).

2.5. Ethics and trial registration

306 The study was ethically reviewed by our Institutional Review Board on February 9th, 2021. 307

The Ethical Committee decided that the study did not require informed consent since the

design did not qualify as a human clinical trial according to applicable national and European

regulations. Only basic demographic data about the room occupants (i.e. age and sex) as

310 well as bed occupancy will be collected anonymously via the electronic health record

database. Still, the head nurses of each ward provided verbal consent to participate

voluntarily in the study, and all staff members were free to adhere to recommendations to

apply mitigation strategies to avoid high indoor CO₂ levels or not. There is no funding

involved in this trial.

285

286

287

288

289

290

291

292

293 294

295

296

297

298

299

300

301

302

303

304

305

308

309

311

312

313

- 315 The trial protocol was registered with ClinicalTrials.gov on February 21st, 2021 (and
- published on February 25th, 2021) at: https://clinicaltrials.gov/ct2/show/NCT04770597. 316
- 317 Previous and future protocol amendments will be registered before publication of the results.
- 318 The full set of data supporting the trial will be made available to established investigators

upon simple request. The authors plan to disseminate the results through international peerreviewed scientific journals.

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

3. DISCUSSION We report here the background, rationale and pilot data that led us to the design of the Monitors to Improve Indoor Carbon Dioxide Concentrations in the Hospital (MICH) trial. There is little doubt that CO₂ monitors can cheaply and accurately measure CO₂ levels in a hospital environment. However, like any technology, implementation requires a behavioral change on the part of caregivers. Thus, our trial classifies as "implementation science", aiming mainly to determine whether nurses and other staff will look at the monitors and increase ventilation, e.g. by operating available HVAC systems, opening windows and/or altering their daily caregiving routines. Indeed, excessive CO₂ levels are caused both by raised production by occupants (too many staff members crowding patient rooms for prolonged times) as well as insufficient CO₂ removal by ventilation. Significant difficulties are expected to implement such behavioral changes, e.g. because caregivers have many other responsibilities, may resist alterations in their work routines, out of concern that increased ventilation leads to draft or temperature discomfort to patients and staff, or concern that windows must remain closed to prevent patients from falling out. A criterion of 10 m² space per person is often recommended to allow social distancing in schools, offices and shops. Given the size of our patient rooms and doctor's office, it is clear that these limits are adequate on average, but that they can be temporarily exceeded by staff occupancy. For example, our doctor's office size is appropriate for two staff geriatricians, but it does not take into account the 3-6 trainees which also need office space. Hospital space is perennially constrained, and the COVID-19 pandemic has spurred further chaotic reorganizations of wards and offices. Thus, continuous attention to office space occupancy in hospitals in required. Moreover, given secular trends in outdoor CO₂ concentrations, ideally CO₂ levels would be monitored simultaneously indoors and outdoors, and referred to in guidelines as p.p.m. above outdoor values, rather than as absolute indoor levels. A major limitation is that our trial is not designed nor powered to determine whether CO₂ monitors reduce the risk of hospital-acquired infections including COVID-19. A first step we want to investigate is whether staff can demonstrate behavioral changes in response to the monitors -if not, then any clinical benefit appears unlikely, and simply recommending monitors with the expectation that they by themselves maintain appropriate CO₂ levels in a

clinical environment would be premature. Moreover, CO₂ is an imperfect proxy of respiratory

- infection risk. Masks or HEPA filters, loud vocalization [33], [34] or physical distancing for
- example, affect pathogen transmission risk without influencing CO₂ levels, while respiratory
- quotient influences CO₂ production independent of exhaled air volume. Another limitation of
- our trial protocol is the single-center open-label design. The latter could not be avoid but
- 356 makes our findings susceptible to observation bias (Hawthorne effect). Due to lack of
- sufficient pilot data, a generic power calculation strategy was applied. Still, to the best of our
- 358 knowledge, this is the first randomized trial aimed to provide a much needed evidence base
- regarding the effectiveness of CO₂ monitors in the hospital environment.

4. REFERENCES

- 361 1. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al.
- 362 Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. N
- 363 Engl J Med. 2020;382(22):2081-90.
- 2. De Smet R, Mellaerts B, Vandewinckele H, Lybeert P, Frans E, Ombelet S, et al.
- 365 Frailty and Mortality in Hospitalized Older Adults With COVID-19: Retrospective
- 366 Observational Study. J Am Med Dir Assoc. 2020;21(7):928-32 e1.
- 367 3. Tang JW, Bahnfleth WP, Bluyssen PM, Buonanno G, Jimenez JL, Kurnitski J, et al.
- Dismantling myths on the airborne transmission of severe acute respiratory syndrome
- 369 coronavirus-2 (SARS-CoV-2). J Hosp Infect. 2021;110:89-96.
- 370 4. Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: A
- 371 Review of Viral, Host, and Environmental Factors. Ann Intern Med. 2021;174(1):69-79.
- 5. Greenhalgh T, Jimenez JL, Prather KA, Tufekci Z, Fisman D, Schooley R. Ten
- 373 scientific reasons in support of airborne transmission of SARS-CoV-2. Lancet. 2021.
- 374 6. Klompas M, Baker MA, Rhee C, Tucker R, Fiumara K, Griesbach D, et al. A SARS-
- 375 CoV-2 Cluster in an Acute Care Hospital. Ann Intern Med. 2021.
- 7. Rose C. Am I Part of the Cure or Am I Part of the Disease? Keeping Coronavirus Out
- 377 When a Doctor Comes Home. N Engl J Med. 2020;382(18):1684-5.
- 378 8. Hogan CA, Gombar S, Wang H, Roltgen K, Shi RZ, Holubar M, et al. Large-Scale
- 379 Testing of Asymptomatic Healthcare Personnel for Severe Acute Respiratory Syndrome
- 380 Coronavirus 2. Emerg Infect Dis. 2021;27(1).
- 381 9. Belosi F, Conte M, Gianelle V, Santachiara G, Contini D. On the concentration of
- 382 SARS-CoV-2 in outdoor air and the interaction with pre-existing atmospheric particles.
- 383 Environ Res. 2021;193:110603.
- 10. Peng Z, Jimenez JL. Exhaled CO2 as a COVID-19 Infection Risk Proxy for Different
- 385 Indoor Environments and Activities. Environ Sci Technol Lett. 2021; published online.
- 386 11. Rudnick SN, Milton DK. Risk of indoor airborne infection transmission estimated from
- carbon dioxide concentration. Indoor Air. 2003;13(3):237-45.

- 388 12. Qian H, Li Y, Nielsen PV, Hyldgaard CE, Wong TW, Chwang AT. Dispersion of
- exhaled droplet nuclei in a two-bed hospital ward with three different ventilation systems.
- 390 Indoor Air. 2006;16(2):111-28.
- 391 13. Shajahan A, Culp CH, Williamson B. Effects of indoor environmental parameters
- 392 related to building heating, ventilation, and air conditioning systems on patients' medical
- outcomes: A review of scientific research on hospital buildings. Indoor Air. 2019;29(2):161-
- 394 76.
- 395 14. Memarzadeh F, Xu W. Role of air changes per hour (ACH) in possible transmission of
- 396 airborne infections. Build Simul. 2012;5(1):15-28.
- 397 15. Superior Health Council of Belgium. Recommendations on the use, outside hospitals
- and care institutions, of passive ventilation systems, mechanical ventilation, air-conditioning
- and filters to prevent potential airborne transmission of SARS-COV-2 Brussels, Belgium:
- 400 Federal Agency for Public Health, Food Safety and Environment; 2020 [Available from:
- 401 https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/200528
- 402 <u>hgr-9599_covid-19_ventilatie_vweb.pdf</u>.
- 403 16. Kaduwela AP, Kaduwela AP, Jrade E, Brusseau M, Morris S, Morris J, et al.
- 404 Development of a low-cost air sensor package and indoor air quality monitoring in a
- 405 California middle school: Detection of a distant wildfire. J Air Waste Manag Assoc.
- 406 2019;69(9):1015-22.
- 407 17. European Centre for Disease Prevention and Control. Heating, ventilation and air-
- 408 conditioning systems in the context of COVID-19: first update Stockholm, Sweden2020
- 409 [Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Heating-
- 410 <u>ventilation-air-conditioning-systems-in-the-context-of-COVID-19-first-update.pdf.</u>
- 411 18. de Man P, Paltansing S, Ong DSY, Vaessen N, van Nielen G, Koeleman JGM.
- 412 Outbreak of COVID-19 in a nursing home associated with aerosol transmission as a result of
- inadequate ventilation. Clin Infect Dis. 2020.
- 414 19. Yang CT, Liao CJ, Liu JC, Den W, Chou YC, Tsai JJ. Construction and application of
- an intelligent air quality monitoring system for healthcare environment. J Med Syst.
- 416 2014;38(2):15.
- 417 20. Ahlawat A, Mishra SK, Birks JW, Costabile F, Wiedensohler A. Preventing Airborne
- 418 Transmission of SARS-CoV-2 in Hospitals and Nursing Homes. Int J Environ Res Public
- 419 Health. 2020;17(22).
- 420 21. Leung M, Chan AH. Control and management of hospital indoor air quality. Med Sci
- 421 Monit. 2006;12(3):SR17-23.
- 422 22. Ramos T, Dedesko S, Siegel JA, Gilbert JA, Stephens B. Spatial and temporal
- 423 variations in indoor environmental conditions, human occupancy, and operational
- characteristics in a new hospital building. PLoS One. 2015;10(3):e0118207.

- 425 23. Zhou Q, Lyu Z, Qian H, Song J, Möbs VC. Field-Measurement of CO₂ Level in
- 426 General Hospital Wards in Nanjing. Procedia Engineering. 2015;121:52-8.
- 427 24. The Truax Group (Healthcare consulting). Yet More Jumps from Hospital Windows
- 428 Grantham, NH2017 [Available from:
- 429 https://www.patientsafetysolutions.com/docs/February 14 2017 Yet More Jumps from Ho
- 430 spital Windows.htm.
- 431 25. Pereira M, Tribess A, Buonanno G, Stabile L, Scungio M, Baffo I. Particle and Carbon
- 432 Dioxide Concentration Levels in a Surgical Room Conditioned with a Window/Wall Air-
- conditioning System. Int J Environ Res Public Health. 2020;17(4).
- 434 26. Kenarkoohi A, Noorimotlagh Z, Falahi S, Amarloei A, Mirzaee SA, Pakzad I, et al.
- Hospital indoor air quality monitoring for the detection of SARS-CoV-2 (COVID-19) virus. Sci
- 436 Total Environ. 2020;748:141324.
- 437 27. Baures E, Blanchard O, Mercier F, Surget E, le Cann P, Rivier A, et al. Indoor air
- 438 quality in two French hospitals: Measurement of chemical and microbiological contaminants.
- 439 Sci Total Environ. 2018;642:168-79.
- 440 28. Tang CS, Chung FF, Lin MC, Wan GH. Impact of patient visiting activities on indoor
- climate in a medical intensive care unit: a 1-year longitudinal study. Am J Infect Control.
- 442 2009;37(3):183-8.
- 443 29. Jung C-C, Wu P-C, Tseng C-H, Su H-J. Indoor air quality varies with ventilation types
- and working areas in hospitals. Building and Environment. 2015;85:190-5.
- 445 30. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al.
- 446 SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med.
- 447 2013;158(3):200-7.
- 448 31. COVID-19 Task Force of REHVA's Technology and Research Committee. COVID-19
- ventilation and building services guidance for school personnel: REHVA; 2020 [Available
- 450 from: https://www.rehva.eu/fileadmin/user_upload/REHVA_COVID-
- 451 19 guidance document School guidance 25112020.pdf.
- 452 32. Huang Q, Marzouk T, Cirligeanu R, Malmstrom H, Eliav E, Ren Y-F. Ventilation rate
- 453 assessment by carbon dioxide levels in dental treatment rooms. medRxiv. 2021:1-26.
- 454 33. Barreda S, Asadi S, Cappa CD, Wexler AS, Bouvier NM, Ristenpart WD. The Impact
- of Vocalization Loudness on COVID-19 Transmission in Indoor Spaces. arXivorg.
- 456 2020:arXiv:2009.04060.
- 457 34. Miller SL, Nazaroff WW, Jimenez JL, Boerstra A, Buonanno G, Dancer SJ, et al.
- 458 Transmission of SARS-CoV-2 by inhalation of respiratory aerosol in the Skaqit Valley
- 459 Chorale superspreading event. Indoor Air. 2021;31(2):314-23.